Back to Search
Start Over
Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy
Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy
- Source :
- BMC Musculoskeletal Disorders
- Publication Year :
- 2016
-
Abstract
- Background Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive muscle degeneration and also high incidence of fractures. The aim of our study was to test whether inhibition of activin receptor IIB ligands with or without exercise could improve bone strength in the mdx mouse model for DMD. Methods Thirty-two mdx mice were divided to running and non-running groups and to receive either PBS control or soluble activin type IIB-receptor (ActRIIB-Fc) once weekly for 7 weeks. Results Treatment of mdx mice with ActRIIB-Fc resulted in significantly increased body and muscle weights in both sedentary and exercising mice. Femoral μCT analysis showed increased bone volume and trabecular number (BV/TV +80%, Tb.N +70%, P
- Subjects :
- Male
Activin Receptors, Type II
Drug Evaluation, Preclinical
Osteoclasts
Bone μCT
Bone and Bones
Mice
TGF-βs
Bone Density
Physical Conditioning, Animal
Animals
Bone Resorption
Muscle, Skeletal
Exercise
Osteoblasts
Organ Size
Muscular Dystrophy, Animal
Combined Modality Therapy
Bone-muscle interactions
Animal models
Mice, Inbred C57BL
Muscular Dystrophy, Duchenne
Disease Models, Animal
Solubility
Mice, Inbred mdx
Research Article
Subjects
Details
- ISSN :
- 14712474
- Volume :
- 18
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMC musculoskeletal disorders
- Accession number :
- edsair.pmid..........bd22f28d0b95eca812c50b63983a4cad